Grifols SA ADR (GRFS)vsEli Lilly and Company (LLY)
GRFS
Grifols SA ADR
$7.64
+0.79%
HEALTHCARE · Cap: $5.20B
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 871% more annual revenue ($72.25B vs $7.44B). LLY leads profitability with a 35.0% profit margin vs 5.6%. GRFS appears more attractively valued with a PEG of 0.23. LLY earns a higher WallStSmart Score of 78/100 (B+).
GRFS
Strong Buy69
out of 100
Grade: B-
LLY
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+23.4%
Fair Value
$12.03
Current Price
$7.64
$4.39 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Earnings expanding 43.5% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
ROE of 7.6% — below average capital efficiency
5.6% margin — thin
Elevated debt levels
Revenue declined 4.8%
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : GRFS
The strongest argument for GRFS centers on PEG Ratio, P/E Ratio, Price/Book. PEG of 0.23 suggests the stock is reasonably priced for its growth.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : GRFS
The primary concerns for GRFS are Return on Equity, Profit Margin, Debt/Equity. Debt-to-equity of 1.77 is elevated, increasing financial risk.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Key Dynamics to Monitor
GRFS profiles as a value stock while LLY is a growth play — different risk/reward profiles.
GRFS carries more volatility with a beta of 1.17 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 69/100), backed by strong 35.0% margins and 55.5% revenue growth. GRFS offers better value entry with a 23.4% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Grifols SA ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Grifols, SA is dedicated to obtaining, manufacturing, preparing and selling therapeutic products, mainly blood derivatives. The company is headquartered in Barcelona, Spain.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?